Kyverna Therapeutics, Inc. (KYTX): Total Liabilities
$61.55M
As of 2025-12-31
$54.27M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.55M | +61.7% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $38.06M | +46.3% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $26.02M | n/a | 2025-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $61.55M | +61.7% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $22.02M | -26.8% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $9.71M | -20.0% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $166.23M | +22.7% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $197.33M | -66.0% |
Compare KYTX, ALEC, XFOR, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗